PDS Biotechnology修改600万美元YA票据条款，新增融资净额强制还债约束

----- ef20081442_8k.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 31, 2026
PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
001-37568
26-4231384
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
303A College Road East
,
Princeton
,
NJ
08540
(Address of Principal Executive Offices, and Zip Code)
(
800
)
208-3343
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
Registered
Common Stock, par value $0.00033 per share
PDSB
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐
Item 1.01
Entry into a Material Definitive Agreement.
On August 31, 2026, PDS Biotechnology Corporation, a Delaware corporation (the “Company”), entered into a First Amendment to
Promissory Note (the “Amendment”) with YA II PN, Ltd. (the “Holder”), which amends that certain Promissory Note made by the Company in favor of the Holder, issued as of June 15, 2026, in the original principal amount of $6,000,000 (the “Note”). The
Amendment made the following modifications to the Note: (i) Section 1(f) of the Note was amended and restated in its entirety to, among other things, require the Company to deliver weekly remittance notices to the Holder setting forth net proceeds
received from sales under the Company’s at-the-market offering program during the prior week and to pay the applicable portion of such net Proceeds within one (1) business day after delivery of such notice; (ii) the cure period for a Nasdaq listing
deficiency under Section 1(g) of the Note was extended from seventy-five (75) days to one-hundred eighty (180) days; and (iii) a new Section 1(i) was added to the Note requiring that 100% of net cash proceeds received from any equity or equity-linked
financing (outside of the Company’s at-the-market offering) be applied as a mandatory deemed redemption payable to the Holder within five (5) business days of receipt. The Amendment becomes effective upon execution and delivery by each party and the
Company having paid in full the installment amount due on the September 14, 2026, pursuant to the terms of the Note.
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full
text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
10.1
First Amendment to Promissory Note, dated as of August 31, 2026, by and between PDS Biotechnology Corporation and YA II PN, Ltd.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
PDS BIOTECHNOLOGY CORPORATION
Date: September 4, 2026
By:
/s/ Frank Bedu-Addo, Ph.D.
Name: Frank Bedu-Addo, Ph.D.
Title: President and Chief Executive Officer

----- ef20081442_ex10-1.htm -----
EX-10.1
2
ef20081442_ex10-1.htm
EXHIBIT 10.1
Exhibit 10.1
FIRST AMENDMENT TO PROMISSORY NOTE
This First Amendment to Promissory Note (this “
Agreement
”) is made as of
August 31, 2026, by and between
PDS BIOTECHNOLOGY CORPORATION
, a Delaware corporation (the “
Company
”),
and
YA II PN, LTD.
(“
Holder
”).
RECITALS
A.
The Company and Holder are parties to that certain
Promissory Note made by the Company in favor Holder, issued as of June 15, 2026 (as amended, supplemented or otherwise modified from time to time, the “
Note
”). Capitalized
terms used herein without definition shall have the meanings ascribed to such terms in the Note.
B.
The Company has requested that Holder make certain
amendments to the Note as more fully described herein and, subject to the express terms and conditions set forth herein, Holder has agreed to Company’s requests.
NOW, THEREFORE,
in consideration of the foregoing premises
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each party hereto, the parties hereby agree as follows:
1.
Amendments
.
(a)
Section 1(f)
of the Note is hereby amended and restated in its entirety as follows:
“(f)
ATM Proceeds
. All net cash proceeds received from sales of Common Shares pursuant to the ATM after the Issuance Date (“
Net Proceeds
”)
shall be applied by the Company to the payment of the Installment Principal Amount (including any increased amortization pursuant to Section (1)(e) above, as it may be decreased under Section 1(d), Section 1(i) and the last sentence of this Section
(1)(f)) due on the next Installment Date (such Installment Date, the “
Next Installment Date
”) and accrued and unpaid interest thereon to the date of such payment, until
such Net Proceeds equal the sum of such Installment Principal Amount and accrued and unpaid interest thereon to the date of prepayment. If the amount of Net Proceeds received after the immediately preceding Installment Date (or after the Issuance
Date, as applicable) and prior to the Next Installment Date exceeds 100% of the sum of the Installment Principal Amount due on the Next Installment Date (as it may be reduced under Section (1)(d), Section 1(i) and this Section (1)(f)) and accrued
and unpaid interest thereon to the date of prepayment, after payment of the Installment Principal Amount due on the Next Installment Date and accrued and unpaid interest thereon through the date of prepayment, 40% of the Net Proceeds may be
retained by the Company and 60% of the Net Proceeds shall be paid by the Company to the Holder and applied to the following monthly Installment Principal Amounts and accrued and unpaid interest thereon to the date of prepayment, in inverse
chronological order. Notwithstanding the foregoing payment timing provisions, the Company shall deliver to the Holder, on a weekly basis (provided Net Proceeds have been received in such prior week), a notice setting forth the aggregate amount of
Net Proceeds received by the Company during the prior week, and the Company shall pay the applicable portion of such Net Proceeds to the Holder within one (1) Business Day of delivery of such remittance notice (with such payments applied in
accordance with this Section 1(f), including the 60/40 allocation for any Net Proceeds in excess of 100% of the Installment Principal Amount and accrued interest due on the Next Installment Date), and interest shall cease to accrue on such paid
amounts of Principal as of the date of such payment.”
(b)
Section 1(g)
of the Note is hereby amended by deleting the reference to “seventy-five (75)” contained therein and replacing it with “one-hundred eighty (180)”.
(c)
The Note is hereby amended by adding the
following new
Section 1(i)
immediately after
Section 1(h)
of the Note:
“(i)
Non-ATM
Offering Proceeds
. If, on or after the Issuance Date, the Company receives cash proceeds from sales of Common
Shares pursuant to an equity or equity linked financing for bona fide capital raising purposes outside of the ATM (“
Non-ATM Offering
”),
t
hen upon receipt of any such net cash proceeds the Company shall be deemed to have delivered to the Holder a Redemption Notice as of the closing date of such Non-ATM Offering with a
Redemption Amount equal to 100% of the amount of such net cash proceeds received from the Non-ATM Offering, and such Redemption Amount shall paid to the Holder within five (5) Business Days of receipt of such net proceeds. Upon receipt by the
Holder, such net proceeds shall be applied to the payment of (i) all accrued and unpaid interest outstanding as of the date of such deemed Redemption Notice, and then (ii) towards the outstanding Principal balance of this Note.
If such redemption is a Redemption in Part, then the amounts paid shall be applied to future monthly Installment Amounts in reverse chronological order
.”
i
2.
Limitations; No Waivers
.
The Company acknowledges and agrees that: (i) Holder does not waive or agree to forbear with respect to, any failure by the Company to perform its
obligations under the Note or with respect to any Event of Default, and Holder does not forbear with respect to any Event of Default, (ii) the execution, delivery, and performance of this Agreement shall not operate as a waiver of, or as an
amendment of, any right, remedy, power or privilege of Holder under the Note as in effect on or prior to the date hereof; and (iii) Holder has not waived any Events of Default or any of its rights or remedies with respect thereto.
3.
Conditions Precedent
.
This Agreement shall become effective on the date when Holder shall have received this Agreement
duly executed and delivered by each of the Company and Holder and the Company having paid in full the Installment Amount due on the September 14, 2026 Installment Date.
4.
Ratification and Affirmation of Note
.
The Company hereby ratifies and affirms the Note and acknowledges that, except as specifically amended by this Agreement, the Note is,
and shall remain, unchanged and in full force and effect in all respects. The Company agrees that the Note constitutes a valid and binding obligation and agreement of the Company enforceable by Holder against the Company in accordance with their
terms. Upon the effectiveness of this Agreement, each reference in the Note to “this Agreement”, “hereunder”, “hereof”, “herein”, or words of like import shall mean and be a reference to the Note as amended by this Agreement, and each reference to
the Note in any other document, instrument or agreement executed and/or delivered in connection with the Note shall mean and be a reference to the Note as amended by this Agreement.
5.
Miscellaneous
.
(a)
Strict Compliance
. Notwithstanding any prior conduct of Holder, Holder hereby demands strict compliance with the terms, provisions, and conditions of the Note.
(b)
Governing Law
.
Section 8
of the Note shall apply herein
as if fully set forth herein,
mutatis mutandis
.
2
(c)
General Acknowledgements
. The Company acknowledges and agrees that neither this Agreement nor any other agreement entered into in connection herewith or pursuant to the terms hereof shall be deemed or construed to be a
satisfaction, reinstatement, accord and satisfaction, novation or release of any amount owed to Holder pursuant to the Note, or any rights or obligations under the Note, or a waiver by Holder of any of its rights under the Note, at law or in
equity.
(d)
Communications and Notices
. All notices, demands or other communications to be given or delivered by reason of the provisions of this Agreement shall be given in accordance with
Section 5
of the Note.
(e)
Time of Essence
. Time is of the essence of this Agreement.
(f)
Tax Consequences
. This Agreement is enforceable regardless of its tax consequences. No party makes any representations with respect to any tax consequences in connection with entry into this Agreement or any payments
required hereunder.
(g)
Binding Effect
. This Agreement and all rights and powers granted hereby will bind and inure to the benefit of the parties hereto and their respective permitted successors and assigns.
(h)
Severability
. In case any provision of or obligation under this Agreement shall be invalid, illegal or unenforceable in any applicable jurisdiction, the validity, legality and enforceability of the remaining provisions or
obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.
(i)
No Third-Party Beneficiaries
. Except as expressly set forth herein, the rights and benefits of this Agreement shall not inure to the benefit of any third party.
(j)
Modifications
. No modification of this Agreement shall be binding or enforceable unless in writing and signed by or on behalf of the party against whom enforcement is sought.
(k)
Headings
. The headings of the sections of this Agreement are inserted for convenience only and shall not be deemed to constitute a part of this Agreement.
(l)
Counterparts
. This Agreement may be executed in counterparts, each of equal import, which, when joined, shall constitute one document. Signatures may be delivered by electronic transmission and such signatures shall be
treated as originals thereof. Any electronic copy of this Agreement, or of any counterpart, shall be deemed to be the equivalent of an original.
(m)
Entire Agreement/Further Assurances
. This Agreement constitutes the entire agreement among the parties concerning the subject matter set forth herein and supersedes any and all prior and contemporaneous agreements,
negotiations, understandings and communications of the parties relating to the subject matter hereof, whether oral or written, with respect thereto. The Company specifically acknowledges and agrees that it is not relying on any oral representation
from Holder or any of its agents. The Company agrees to execute and deliver to Holder such other and further documentation and to undertake such further actions as Holder shall deem necessary to effectuate the provisions of this Agreement. The
Company acknowledges and agrees that each of the Recitals is true and correct in all respects and incorporated herein by reference, as though fully set forth herein.
3
(n)
Reviewed by Attorneys
. The Company represents and warrants to Holder that it (a) understands fully the terms of this Agreement and the consequences of the execution and delivery of this Agreement, (b) has been afforded an
opportunity to discuss this Agreement with, and have this Agreement reviewed by, such attorneys and other persons as the Company may wish, and (c) has entered into this Agreement and executed and delivered all documents in connection herewith of
its own free will and accord and without threat, duress or other coercion of any kind by any Person. The parties hereto acknowledge and agree that neither this Agreement nor the other documents executed pursuant hereto will be construed more
favorably in favor of one than the other based upon which party drafted the same, it being acknowledged that all parties hereto contributed substantially to the negotiation and preparation of this Agreement and the other documents executed pursuant
hereto or in connection herewith.
[Signature Page Follows]
4
IN WITNESS WHEREOF,
the parties hereto have caused this
Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the date first written above.
COMPANY:
PDS BIOTECHNOLOGY CORPORATION
By:
/s/ Frank Bedu-Addo
Name:
Frank Bedu-Addo
Title:
Chief Executive Officer
HOLDER:
YA II PN, LTD.
By:
Yorkville Advisors Global, LP
Its:
Investment Manager
By: Yorkville Advisors Global II, LLC
Its: General Partner
By:
/s/ Matt Beckman
Name:
Matt Beckman
Title:
Member
​